We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanoscale Biosensor for Detection of Pathogenic Bacteria under Field Conditions

By LabMedica International staff writers
Posted on 27 Jun 2016
Image: A colorized scanning electron micrograph (SEM) showing a number of Gram-negative Escherichia coli bacteria of the strain O157:H7 (Photo courtesy of the CDC).
Image: A colorized scanning electron micrograph (SEM) showing a number of Gram-negative Escherichia coli bacteria of the strain O157:H7 (Photo courtesy of the CDC).
A team of bioengineers used nanoscale technology to develop a simple, portable biosensor system for detection of pathogenic bacteria – such as the diarrhea-causing Escherichia coli (E. coli) 0157:H7 – under field conditions.

Investigators at Washington State University (Pullman, USA) used organic and inorganic components to create nanoparticles, which resembled miniature flowers under the microscope. These "nanoflowers" provided a large surface area for immobilizing the enzymes that needed to detect low levels of the bacteria. Binding of the specific target bacteria triggered a change in acidity that was amplified to be measurable on a handheld pH meter or with a pH indicator paper strip.

“We want to take these nanoflowers and create a simple-to-use, handheld device that anyone can use anywhere,” said senior author Dr. Yuehe Lin, professor of mechanical and materials engineering at Washington State University. “It will be as simple as using a pregnancy test strip or a glucose meter.”

A patent application has been filed for the methodology, which was also described in the June 15, 2016, issue of the journal Small.

Related Links:
Washington State University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Immunoassay Analyzer
SuperFlex™
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood

Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more